Why the study?
Does trimetazidine improve clinical outcomes in patients with systolic heart failure?
Population
Patients with systolic heart failure
Design
Review
Authors
Loading...
May support adjunctive use in systolic HF; leaves open confirmation in large contemporary RCTs.
Does trimetazidine improve clinical outcomes in patients with systolic heart failure?
Trimetazidine, a metabolic agent, shows promise in improving cardiac function and reducing mortality in heart failure by optimizing cardiac energetics, though larger trials are needed.
Akshyay Pradhan (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: